Core Viewpoint - The company, Sai Sheng Pharmaceutical (300485), reported that as of November 20, 2025, the number of shareholders is 37,118 [1] Summary by Categories - **Company Information** - As of November 20, 2025, the total number of shareholders for Sai Sheng Pharmaceutical is 37,118 [1]

Market Overview - The biopharmaceutical sector increased by 0.83% on November 25, with Jindike leading the gains [1] - The Shanghai Composite Index closed at 3870.02, up 0.87%, while the Shenzhen Component Index closed at 12777.31, up 1.53% [1] Top Gainers in Biopharmaceutical Sector - Jinke (688670) closed at 25.75, up 19.99% with a trading volume of 92,200 shares [1] - Hualan Biological (301207) closed at 23.33, up 11.25% with a trading volume of 250,500 shares [1] - Saiseng Pharmaceutical (300485) closed at 11.95, up 5.19% with a trading volume of 168,000 shares [1] - Other notable gainers include Bohui Innovation (300318) at 6.84 (+3.32%) and Dongbao Biological (300239) at 5.72 (+3.25%) [1] Market Capital Flow - The biopharmaceutical sector saw a net inflow of 40.88 million yuan from institutional investors, while retail investors experienced a net outflow of 147 million yuan [2] - The sector's overall capital flow indicates a strong interest from institutional investors despite retail selling pressure [2] Individual Stock Capital Flow - Jinke (688670) had a net inflow of 39.66 million yuan from institutional investors, while retail investors showed a net outflow of 13.72 million yuan [3] - Other stocks like Watson Bio (300142) and Hualan Bio (002007) also experienced significant net inflows from institutional investors, indicating positive sentiment [3] - Conversely, stocks like Dongbao Biological (300239) and Bohui Innovation (300318) faced net outflows from retail investors, suggesting mixed investor sentiment [3]

Group 1 - The demand for flu-related medications is rising significantly as the flu season approaches, with several stocks in the sector experiencing price surges [1] - Notable stocks that have reached their daily limit include Jindike, Peking University Medicine, and Te Yi Pharmaceutical, among others [1] - Data from Alibaba Health indicates a more than 500% week-on-week increase in the number of people purchasing antiviral flu medications, with Mabalosavir showing a remarkable over 600% increase [1] Group 2 - Experts warn that the H3N2 strain circulating this year is different from previous years, leading to lower immunity in the population and increased transmission risk [2] - The flu virus is known to undergo antigenic drift, but current strains are still within seasonal levels and do not indicate a stronger evolution of the virus [2] Group 3 - Companies are actively ensuring the supply of flu medications and vaccines in response to rising demand [3] - Dongyang Sunshine, a major supplier of Oseltamivir, reports comprehensive coverage of its products across hospitals, pharmacies, and online platforms, maintaining sufficient inventory [3] - Hualan Biological has noted a significant increase in demand for flu vaccines since October, with plans to enhance market supply and ensure timely delivery through cold chain logistics [3]

Group 1 - The core point of the article is that Sai Sheng Pharmaceutical announced that its subsidiary, Shenyang Junyuan Pharmaceutical Co., Ltd., has received a drug production license from the Liaoning Provincial Drug Administration [2] - The announcement includes a change in the production manager from Li Li to Liu Huifeng, while other details remain unchanged [2]

Core Viewpoint - The announcement indicates that Junyuan Pharmaceutical, a subsidiary of Saiseng Pharmaceutical, has received a drug production license from the Liaoning Provincial Drug Administration, which is expected to maintain stable production capacity without significant impact on the company's performance [1] Group 1 - Junyuan Pharmaceutical has been granted a drug production license with the license number Liao 20210198, valid until April 7, 2026 [1] - The production manager has been changed from Li Li to Liu Huifeng, while other details remain unchanged [1] - The change is beneficial for maintaining stable production capabilities and ensuring normal business operations [1]

Core Viewpoint - Sai Sheng Pharmaceutical (300485.SZ) announced that its subsidiary, Shenyang Junyuan Pharmaceutical Co., Ltd., has recently obtained a Drug Manufacturing License from the Liaoning Provincial Drug Administration, with a change in the production responsible person from Li Li to Liu Huifeng, while other details remain unchanged [1] Company Summary - Sai Sheng Pharmaceutical's subsidiary, Shenyang Junyuan Pharmaceutical, has received a Drug Manufacturing License [1] - The change in the production responsible person is a key update, with Liu Huifeng taking over from Li Li [1] - Other aspects of the license remain unchanged, indicating stability in operations [1]

社会信用代码：91210112MA0P430D6R 关于子公司药品生产许可证变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 北京赛升药业股份有限公司（以下简称"公司"）子公司沈阳君元药业有限 公司（以下简称"君元药业"）近日获得了辽宁省药品监督管理局颁发的《药品 生产许可证》。本次涉及变更的事项为：同意该企业生产负责人由李莉变更为刘 慧凤，其他内容不变。现将相关信息公告如下： 一、《药品生产许可证》的基本信息 企业名称：沈阳君元药业有限公司 许可证编号：辽 20210198 证券代码：300485 证券简称：赛升药业 公告编号：2025-050 北京赛升药业股份有限公司 分类码：AhzBh 注册地址：沈阳市浑南区麦子屯 603 号沈阳浑南生物医药产业园 9 号楼 有效期至：2026 年 04 月 07 日 法定代表人：王雪峰 企业负责人：王光 生产负责人：刘慧凤 二、对公司的影响 本次《药品生产许可证》涉及企业生产负责人变更，有利于君元药业继续保 持稳定的生产能力，确保君元药业的正常生产经营，不会对公司业绩产生重大影 响。敬请广大投资者理性投资，注 ...

Core Insights - The biopharmaceutical sector experienced a decline of 0.98% on November 18, with He Yuan Bio leading the drop [1] - The Shanghai Composite Index closed at 3939.81, down 0.81%, while the Shenzhen Component Index closed at 13080.49, down 0.92% [1] Stock Performance Summary - Notable gainers included: - Aopu Mai (688293) with a closing price of 58.80, up 3.38% on a trading volume of 15,900 shares and a transaction value of 93.39 million [1] - Jin Hu Ke (688670) at 26.80, up 2.88% with a volume of 116,300 shares and a transaction value of 319 million [1] - Te Bao Bio (688278) at 77.08, up 1.22% with a volume of 10,800 shares and a transaction value of 82.57 million [1] - Notable decliners included: - Bu Yuan Bio (688765) at 79.95, down 3.89% with a volume of 56,800 shares and a transaction value of 458 million [2] - San Sheng Guo Jian (688336) at 67.60, down 3.87% with a volume of 68,100 shares and a transaction value of 469 million [2] - Wo Wu Bio (300357) at 31.77, down 3.23% with a volume of 77,900 shares and a transaction value of 250 million [2] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 981 million from institutional investors, while retail investors contributed a net inflow of 819 million [2] - Key stocks with significant capital flow included: - Hua Lan Vaccine (301207) with a net inflow of 48.51 million from institutional investors [3] - Rong Chang Bio (688331) with a net inflow of 23.62 million from institutional investors [3] - Jin Ke (688670) with a net inflow of 5.53 million from institutional investors [3]

Core Insights - The company, Sai Sheng Pharmaceutical, reported that as of November 10, 2025, the number of shareholders is 35,647 [2] Summary by Category - **Company Information** - As of November 10, 2025, the total number of shareholders for Sai Sheng Pharmaceutical is 35,647 [2]

Market Overview - The biopharmaceutical sector increased by 0.3% on November 14, with Jindike leading the gains [1] - The Shanghai Composite Index closed at 3990.49, down by 0.97%, while the Shenzhen Component Index closed at 13216.03, down by 1.93% [1] Stock Performance - Jindike (688670) closed at 28.03, up by 19.99% with a trading volume of 105,500 shares and a transaction value of 270 million [1] - Hualan Ting (301207) closed at 25.38, up by 7.22% with a trading volume of 336,800 shares [1] - Other notable performers include: - Saikai Pharmaceutical (300485) at 13.35, up by 4.54% [1] - Olin Bio (616889) at 24.81, up by 4.29% [1] - Wowo Bio (300357) at 33.65, up by 3.03% [1] Capital Flow - The biopharmaceutical sector experienced a net outflow of 59.84 million from institutional investors, while retail investors saw a net inflow of 23.85 million [2][3] - Key stocks with significant capital flow include: - Ganli Pharmaceutical (603087) with a net inflow of 62.98 million from institutional investors [3] - Jindike (688670) with a net inflow of 40.32 million from institutional investors [3] - Hualan Ting (301207) with a net inflow of 27.99 million from institutional investors [3]